EUVIMEDEUVIMED entdecken
Open Access

Construction of a ubiquitination-related gene signature to predict prognosis and treatment response in lung adenocarcinoma

Xue Li, Jianian Lai, Meifang Guo, Zhen Lian

Pakistan Journal of Medical Sciences · 06.03.2026 · 42 (3) · 715-724

DOI: 10.12669/pjms.42.3.13747 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pakistan Journal of Medical Sciences, online erschienen am 06.03.2026. Verfasst von Xue Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Xue Li Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key …. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Objective: The prognosis of lung adenocarcinoma (LUAD) remains poor, primarily due to treatment resistance and a lack of effective biomarkers. This research investigated the potential of ubiquitination-related genes (UbRG) as prognostic indicators for LUAD. Methodology: This study was conducted at Tianjin Medical University Cancer Institute and Hospital from May 2025 to October 2025. Leveraging data from TCGA, we initially employed WGCNA to identify key modules of UbRG associated with LUAD. Then, a multigene prognostic signature was developed. To investigate the mechanisms, GSEA and CIBERSORT were used to detect activated signaling pathways and immune landscape, respectively. Finally, drug sensitivity analysis was performed.

Results

Our analysis identified nine gene pairs that constitute the UbRG prognostic signature, with individuals in the high-risk cohort generally experiencing worse outcomes. Pathway enrichment analyses revealed immune response pathways in the low-risk cohort and the cell cycle and DNA replication pathways in the high-risk cohort. CIBERSORT revealed distinct immune cell distributions, with more CD4+ T cells and DCs in the low-risk cohort. Drug sensitivity analysis suggest that the low-risk group may exhibit a greater sensitivity to both chemotherapy and targeted treatments.

Conclusion

This study presents a novel UbRG signature for LUAD prognosis, emphasizing the role of ubiquitination in the immune response. These findings may guide future therapeutic strategies in LUAD.

Schlagwörter

Stichwörter der Autor:innen

Cancer immunityLung adenocarcinomaPrognosisUbiquitination

Autor:innen und Institutionen

  • Xue Li Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Resear…
  • Jianian Lai Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical R…
  • Meifang Guo Department of Ultrasonic Diagnosis, The Second People's Hospital of Dongying, Dongying 257200, Shandong, China.
  • Zhen Lian Department of Emergency, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Cen…

Zitieren

APA

Li, X., Lai, J., Guo, M., & Lian, Z. (2026). Construction of a ubiquitination-related gene signature to predict prognosis and treatment response in lung adenocarcinoma. Pakistan Journal of Medical Sciences, 42(3), 715-724. https://doi.org/10.12669/pjms.42.3.13747

Vancouver

Li X, Lai J, Guo M, Lian Z. Construction of a ubiquitination-related gene signature to predict prognosis and treatment response in lung adenocarcinoma. Pakistan Journal of Medical Sciences. 2026;42(3):715-724. doi:10.12669/pjms.42.3.13747

BibTeX
@article{Li2026,
  author = {Li, Xue and Lai, Jianian and Guo, Meifang and Lian, Zhen},
  title = {Construction of a ubiquitination-related gene signature to predict prognosis and treatment response in lung adenocarcinoma},
  journal = {Pakistan Journal of Medical Sciences},
  year = {2026},
  volume = {42},
  number = {3},
  pages = {715--724},
  doi = {10.12669/pjms.42.3.13747}
}
Kostenlos starten →